Qiagen Beheer

Beheer criteriumcontroles 4/4

De CEO Qiagen is Thierry Bernard, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.99M, bestaande uit 49.1% salaris en 50.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde € 13.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 9.6 jaar.

Belangrijke informatie

Thierry Bernard

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris	49.1%
Dienstverband CEO	5.1yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	9.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thierry Bernard's beloning veranderd ten opzichte van Qiagen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$93m
Jun 30 2024	n/a	n/a	US$73m
Mar 31 2024	n/a	n/a	US$337m
Dec 31 2023	US$2m	US$979k	US$341m
Sep 30 2023	n/a	n/a	US$332m
Jun 30 2023	n/a	n/a	US$337m
Mar 31 2023	n/a	n/a	US$353m
Dec 31 2022	US$10m	US$950k	US$423m
Sep 30 2022	n/a	n/a	US$488m
Jun 30 2022	n/a	n/a	US$539m
Mar 31 2022	n/a	n/a	US$563m
Dec 31 2021	US$2m	US$900k	US$513m
Sep 30 2021	n/a	n/a	US$311m
Jun 30 2021	n/a	n/a	US$480m
Mar 31 2021	n/a	n/a	US$449m
Dec 31 2020	US$2m	US$900k	US$359m
Sep 30 2020	n/a	n/a	US$191m
Jun 30 2020	n/a	n/a	US$14m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$650k	-US$41m

Compensatie versus markt: De totale vergoeding ($USD 1.99M ) Thierry } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.58M ).

Compensatie versus inkomsten: De vergoeding van Thierry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Thierry Bernard (60 yo)

5.1yrs

Tenure

US$1,991,874

Compensatie

Mr. Thierry Bernard serves as Director of Neogen Corporation since November 01, 2024. He has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thierry Bernard	CEO, MD & Member of Management Board	5.1yrs	US$1.99m	0.14% € 13.1m
Roland Sackers	CFO, MD & Member of Management Board	20.8yrs	US$1.07m	0.19% € 17.1m
Antonio Santos	Senior VP & Head of Global Operations	2.6yrs	geen gegevens	geen gegevens
John Gilardi	Vice President of Corporate Communications & Investor Relations	14.1yrs	geen gegevens	geen gegevens
Stephany Foster	Senior VP & Head of Human Resources	5.1yrs	geen gegevens	geen gegevens
Thomas Schweins	Senior Vice President of Life Science Business Area	6.8yrs	geen gegevens	geen gegevens
Thomas Theuringer	Senior Director & Head of External Communications	no data	geen gegevens	geen gegevens
Jean-Pascal Viola	Senior VP & Head of Corporate Strategy and Business Development	9.5yrs	geen gegevens	geen gegevens
Jonathan Sheldon	Senior VP & Head of the QIAGEN Digital Insights Business Area	6.8yrs	geen gegevens	geen gegevens
Fernando Beils	Senior VP & Head of the Molecular Diagnostics Business Area	no data	geen gegevens	geen gegevens
Nitin Sood	Senior VP & Head of the Life Sciences Business Area	no data	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QIA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Rusckowski	Independent Member of Supervisory Board	1.6yrs	US$46.07k	0.000010% € 905.1
Metin Colpan	Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board	20.8yrs	US$86.50k	0.080% € 7.2m
Elizabeth Tallett	Independent Member of the Supervisory Board	13.4yrs	US$101.50k	0.022% € 2.0m
Eva Pisa	Independent Member of the Supervisory Board	2.4yrs	US$68.50k	geen gegevens
Lawrence Rosen	Independent Chairman of Supervisory Board	11.4yrs	US$188.50k	0.0067% € 607.3k
Toralf Haag	Independent Member of the Supervisory Board	3.8yrs	US$82.50k	0.0012% € 106.8k
Elaine Mardis	Independent Member of the Supervisory Board	10.4yrs	US$79.50k	0.0018% € 166.5k
Peter Kaspar	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ross Levine	Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board	8.8yrs	US$68.50k	0.0075% € 681.5k
Patrice Nordmann	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Neville Sanjana	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sarah Polonius-Teichmann	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens

9.6yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QIA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).

Qiagen Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V., Annual General Meeting, Jun 21, 2024

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Board Member recently sold €204k worth of stock

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

Recent updates

Qiagen Collaborates with McGill University to Advance Microbiome Research

Third quarter 2024 earnings released: EPS: US$0.44 (vs US$0.35 in 3Q 2023)

Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024

QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics

QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment

QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications

Qiagen N.V. to Report Q3, 2024 Results on Nov 06, 2024

QIAGEN N.V. Launches QIAcuityDx Digital PCR System for Clinical Testing in Oncology

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

CFO, MD & Member of Management Board recently sold €677k worth of stock

Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care

Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine

QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret

Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results

Qiagen N.V., Annual General Meeting, Jun 21, 2024

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.39 in 1Q 2023)

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Full year 2023 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022)

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022)

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued after recent price drop

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings: EPS misses analyst expectations

Board Member recently sold €204k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

Now 20% undervalued

Now 21% undervalued

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Now 21% undervalued after recent price drop

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

Price target increased to €50.58

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency